fashion -WSS

fashion

author：knowledge 2025-09-28 21:56:38 - browse：27

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

WSS

RSV vaccines may be linked to small increased risk of developing GBS

Naloxone nonprofit donates 200,000 doses after FDA approval

Kenai launches with $82 million for Parkinson’s stem cell therapy

Why failed clinical trials don’t always spell doom for a new drug

Medical device lobby: We're tired of waiting on Medicare coverage

American woman, child freed after being kidnapped in Haiti last month

focus

fashion

focus

How to save PrEP access — and even expand it

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Anesthesiologist group: stop taking Ozempic before surgery

Anavex keeps shifting the goalposts in its clinical trials

Walensky prepares to leave CDC — and Congress — behind

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Malaria cases in Florida and Texas: Here’s what you need to know

House looks to weaken Medicare negotiation

Jerome Adams on the need for new antivirals for Covid

Obesity now affects over 1 billion people worldwide, study finds

focus

Flu vaccine offering decent levels of protection this winter, new data show

Man killed during FBI raid in connection with threats against Biden, other officials

Wegovy’s successful heart trial raises vital question about weight loss

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Change Healthcare cyberattack outage could last weeks

International team creates first chimeric human

hotspot

explore

hotspot

hotspot